Nevro Corp. (NVRO)
Stock Price:
$171.03 USD
2.06 (1.22%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
5.89B |
| Revenue (ttm) |
366.69M |
| Net Income (ttm) |
-89.68M |
| Shares Out |
34.43M |
| EPS (ttm) |
-2.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$171.03 |
| Previous Close |
$168.97 |
| Change ($) |
2.06 |
| Change (%) |
1.22% |
| Day's Open |
168.60 |
| Day's Range |
167.55 - 171.44 |
| Day's Volume |
76,808 |
| 52-Week Range |
65.05 - 175.71 |
More Stats
| Market Cap |
5.89B |
| Enterprise Value |
5.64B |
| Earnings Date (est) |
Feb 25, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.43M |
| Float |
33.07M |
| EPS (basic) |
-2.72 |
| EPS (diluted) |
-2.73 |
| FCF / Share |
-0.84 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.57M |
| Short Ratio |
8.24 |
| Short % of Float |
7.76% |
| Beta |
1.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
16.06 |
| PB Ratio |
15.53 |
| Revenue |
366.69M |
| Operating Income |
-73.66M |
| Net Income |
-89.68M |
| Free Cash Flow |
-28.96M |
| Net Cash |
250.05M |
| Net Cash / Share |
7.26 |
| Gross Margin |
73.18% |
| Operating Margin |
-20.09% |
| Profit Margin |
-24.50% |
| FCF Margin |
-7.90% |
| ROA |
-7.35% |
| ROE |
-31.04% |
| ROIC |
-12.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (15)
| Buy |
11 |
| Overweight |
1 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$174.58*
(2.08% upside)
Low
150
Current: $171.03
High
190
Target: 174.58
*Average 12-month price target from 12 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 390 | 387 | 327 | 229 | 69.61 | 32.57 | 23.50 | 18.15 |
| Revenue Growth | 0.77% | 18.56% | 42.96% | 228.28% | 113.69% | 38.61% | 29.48% | - |
| Gross Profit | 268 | 273 | 228 | 153 | 41.49 | 21.30 | 14.03 | 10.62 |
| Operating Income | -96.48 | -41.74 | -29.58 | -23.08 | -62.37 | -28.31 | -25.15 | -19.13 |
| Net Income | -104 | -49.21 | -36.66 | -31.78 | -67.43 | -30.68 | -26.01 | -18.97 |
| Shares Outstanding | 30.80 | 30.05 | 29.42 | 28.49 | 26.58 | 4.44 | 0.88 | 0.49 |
| Earnings Per Share | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.94 | -29.84 | -38.59 |
| Operating Cash Flow | -50.23 | -5.71 | -14.27 | -58.50 | -100 | -31.15 | -21.10 | -22.47 |
| Capital Expenditures | -3.47 | -8.22 | -4.33 | -3.37 | -5.01 | -0.63 | -0.06 | -0.03 |
| Free Cash Flow | -53.70 | -13.93 | -18.60 | -61.87 | -105 | -31.77 | -21.15 | -22.50 |
| Cash & Equivalents | 239 | 265 | 270 | 277 | 195 | 177 | 56.83 | 56.83 |
| Total Debt | 181 | 152 | 145 | 138 | 19.74 | 19.51 | - | - |
| Net Cash / Debt | 58.01 | 113 | 125 | 139 | 175 | 158 | 56.83 | 56.83 |
| Assets | 470 | 463 | 454 | 431 | 291 | 202 | 75.41 | 75.41 |
| Liabilities | 253 | 218 | 205 | 182 | 56.59 | 30.43 | 7.97 | 7.97 |
| Book Value | 216 | 245 | 249 | 249 | 235 | 172 | -85.79 | -85.79 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Nevro Corp. |
| Country |
United States |
| Employees |
853 |
| CEO |
D. Keith Grossman |
Stock Information
| Ticker Symbol |
NVRO |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NYSE: NVRO |
| IPO Date |
November 6, 2014 |
Description
Nevro, a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.